Overlapping Receptor-Based Pathogenic Cascades in Degenerative Disease: Implications Ranging from Tumor Targeting to Aging and Dementia Therapeutics DOI Creative Commons
Joseph D’Arrigo

International Journal of Translational Medicine, Год журнала: 2024, Номер 4(1), С. 152 - 162

Опубликована: Фев. 6, 2024

Previous research has already shown that apolipoprotein (apo)A-I is adsorbed from the bloodstream onto surface of certain colloidal lipid particles after intravenous injection such nanocarriers. As a result, various blood–brain barrier (BBB) scavenger receptors are targeted by these (apoA-I-coated) This molecular interaction mediated/facilitated apoA-I, which then followed receptor-mediated endocytosis and subsequent transcytosis nanocarrier across BBB. A multifunctional combination therapy obtained adding appropriate drug(s) to biomimetic (lipid cubic phase) therapeutic targets specific cell-surface receptors, primarily class B type I (SR-BI), crosses barrier. The contents artificial (nanoemulsion) naturally occurring high-density lipoproteins (HDL) have been be similar, enables partially imitate or simulate known heterogeneity (i.e., subpopulations subspecies) HDL particles. Hence, drug nanocarriers potential used in biomedical treatment complicated medical conditions including dementia, as well elements aging. Widespread inflammation oxidative stress—two processes include several pathophysiological cascades—are brought on dementia risk factors. More recent studies suggest proinflammatory cytokines may released response prolonged inflammatory stimulus gut, for example through serum amyloid (SAA). Therefore, pharmacologically targeting major SAA receptor implicated SAA-mediated cell signaling cause aging and/or cognitive decline, ultimately Alzheimer’s disease (late-onset) could an effective preventive approach.

Язык: Английский

Developing Non-Invasive Molecular Markers for Early Risk Assessment of Alzheimer's Disease DOI Creative Commons

Tapas Kumar Sur,

Tanmoy Mondal, Zarish Noreen

и другие.

Biomarkers in Neuropsychiatry, Год журнала: 2025, Номер unknown, С. 100120 - 100120

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Regional brain structural alterations in reward and salience networks in asthma DOI

Danielle Carrol,

William W. Busse, Corrina Frye

и другие.

Brain Behavior and Immunity, Год журнала: 2025, Номер 126, С. 80 - 97

Опубликована: Фев. 5, 2025

Язык: Английский

Процитировано

0
RhoA/ROCK/GSK3β Signaling: A Keystone in Understanding Alzheimer’s Disease DOI Creative Commons

Milan M. Medd,

Jiang Yon,

Hongxin Dong

и другие.

Current Issues in Molecular Biology, Год журнала: 2025, Номер 47(2), С. 124 - 124

Опубликована: Фев. 14, 2025

Alzheimer's disease (AD) is a neurodegenerative characterized by progressive cognitive decline and loss of neuronal integrity. Emerging evidence suggests that RhoA, Rho-associated coiled-coil kinase (ROCK), their downstream effector molecule glycogen synthase 3β (GSK3β) interact within complex signaling pathway (RhoA/ROCK/GSK3β) plays crucial role in the pathogenesis AD. small GTPase, along with its effector, ROCK, regulates various cellular processes, including actin cytoskeleton dynamics, apoptosis, synaptic plasticity. GSK3β, serine/threonine kinase, key function AD pathology, regulation tau phosphorylation amyloid-beta cleavage. Overactive GSK3β has been closely linked to hyperphosphorylation, neurodegeneration, progression Thus, considered as promising therapeutic target for treating mitigating impairment. However, clinical trials have faced considerable challenges due complexity specific inhibition GSK3β. In this review, we summarize literature regarding relationship RhoA/ROCK pathways pathogenesis. We further discuss recent findings sTREM2-transgelin-2 (TG2) axis potential mediator provide our review on novel targeting strategy

Язык: Английский

Процитировано

0
The Neuroimmune Axis in Gastrointestinal Disorders – An Underrecognized Problem DOI
Laura Pace,

Niwen Kong,

Mohamed I Itani

и другие.

Current Gastroenterology Reports, Год журнала: 2025, Номер 27(1)

Опубликована: Апрель 15, 2025

Язык: Английский

Процитировано

0
Association between air quality and neurodegenerative diseases in River Sacco Valley: A retrospective cohort study in Latium, central Italy DOI

Alessandro Trentalange,

Chiara Badaloní, Daniela Porta

и другие.

International Journal of Hygiene and Environmental Health, Год журнала: 2025, Номер 267, С. 114578 - 114578

Опубликована: Апрель 16, 2025

Язык: Английский

Процитировано

0
Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil DOI Creative Commons
Price Udo Price, Robert Heggie, Júlio César Moriguti

и другие.

Value in Health Regional Issues, Год журнала: 2025, Номер 49, С. 101130 - 101130

Опубликована: Май 27, 2025

Язык: Английский

Процитировано

0
Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes DOI Creative Commons
Jung‐Min Pyun, Young Ho Park, Min Ju Kang

и другие.

Alzheimer s Research & Therapy, Год журнала: 2024, Номер 16(1)

Опубликована: Окт. 2, 2024

Язык: Английский

Процитировано

1
Overlapping Receptor-Based Pathogenic Cascades in Degenerative Disease: Implications Ranging from Tumor Targeting to Aging and Dementia Therapeutics DOI Creative Commons
Joseph D’Arrigo

International Journal of Translational Medicine, Год журнала: 2024, Номер 4(1), С. 152 - 162

Опубликована: Фев. 6, 2024

Previous research has already shown that apolipoprotein (apo)A-I is adsorbed from the bloodstream onto surface of certain colloidal lipid particles after intravenous injection such nanocarriers. As a result, various blood–brain barrier (BBB) scavenger receptors are targeted by these (apoA-I-coated) This molecular interaction mediated/facilitated apoA-I, which then followed receptor-mediated endocytosis and subsequent transcytosis nanocarrier across BBB. A multifunctional combination therapy obtained adding appropriate drug(s) to biomimetic (lipid cubic phase) therapeutic targets specific cell-surface receptors, primarily class B type I (SR-BI), crosses barrier. The contents artificial (nanoemulsion) naturally occurring high-density lipoproteins (HDL) have been be similar, enables partially imitate or simulate known heterogeneity (i.e., subpopulations subspecies) HDL particles. Hence, drug nanocarriers potential used in biomedical treatment complicated medical conditions including dementia, as well elements aging. Widespread inflammation oxidative stress—two processes include several pathophysiological cascades—are brought on dementia risk factors. More recent studies suggest proinflammatory cytokines may released response prolonged inflammatory stimulus gut, for example through serum amyloid (SAA). Therefore, pharmacologically targeting major SAA receptor implicated SAA-mediated cell signaling cause aging and/or cognitive decline, ultimately Alzheimer’s disease (late-onset) could an effective preventive approach.

Язык: Английский

Процитировано

0